Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-210 mimic
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intrathecal, Intravenous, Subcutaneous
01
Overview
microRNA-210 mimic (also known as miR-210 mimic or agomiR-210) is a synthetic, double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-210 (miR-210). As a key hypoxia-responsive microRNA regulated by hypoxia-inducible factors (HIF), miR-210 plays a critical role in cell survival, mitochondrial metabolism, and angiogenesis. The mimic functions by binding to the messenger RNAs (mRNAs) of target genes, such as STAT6, APC, ISCU, and various ER-stress and apoptotic genes, thereby regulating their translation or stability. Although primarily utilized as a research-use-only reagent, preclinical studies have investigated its therapeutic potential in promoting wound healing in diabetic models, improving cardiac function in ischemic heart disease, and facilitating neurological recovery in spinal cord injury.
- Other names
- agomiR-210agomiR210agomiR 210miR-210 mimicmiR210 mimicmiR 210 mimic
Beyond the preview
Go deeper on microRNA-210 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-210 mimic.